Q1 2023 Results
Company overview
Financial review
Innovation: Pipeline overview
Financial performance
Cardiovascular
Immunology
iptacopan - CFB inhibitor
NCT04578834 APPLAUSE-IgAN (CLNP023A2301)
Indication
IgA nephropathy
Phase 3
Conclusions
Appendix
Innovation: Clinical trials
Neuroscience
Oncology
Phase
Patients
450
Primary
Outcome
Measures
Arms
Intervention
Target
Patients
Readout
Milestone(s)
Publication
Ratio to baseline in urine protein to creatinine ratio (sampled from 24h urine
collection) at 9 months
Annualized total estimated Glomerular Filtration Rate (eGFR) slope estimated
over 24 months
Arm 1 - LNP023 200mg BID
Arm 2 Placebo BID
Primary IgA Nephropathy patients
2023 (primary endpoint for US initial submission, 9 months UPCR)
2025 (24 months)
Perkovic et al. 2021, Nephrology Dialysis Transplantation, Vol. 36, Suppl. 1:
Study Design
46 Investor Relations | Q1 2023 Results
References
Abbreviations
Other
NOVARTIS | Reimagining MedicineView entire presentation